Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224139 · ClinicalTrials.gov registry record
Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias
A clinical trial of Alzheimer Disease and Dementia, sponsored by Anne Murray.
- Active
- Registry status
- 13,435
- Enrollment target
- 5
- Study locations
NCT07224139: Active study of Alzheimer Disease and Dementia, sponsored by Anne Murray.
NCT07224139 is a study of Alzheimer Disease and Dementia that is active but no longer recruiting, run by Anne Murray. The registered enrollment target is 13,435 participants, above the 2,707-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (396% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224139, a study of Alzheimer Disease and Dementia, is active but no longer recruiting, sponsored by Anne Murray.
- ACTIVE NOT RECRUITING
- Registry status
- 13,435 participants
- Enrollment target
- 5
- Study locations
Study Summary
Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for personalized medicine and clinical trials.
Primary Outcome
We hypothesize that: 1a. There will be sex differences in the cross-sectional biomarker levels, and in their trajectories over time. 1b. Chronic comorbidities and genetic risk factors (APOE ε4, polygenic risk score) will be associated with 'worse' AT(N) biomarker levels (reflecting worse ADRD pathology) at baseline and with a greater increase over time over time, and that these associations will differ between men and women.
Conditions Studied
Study Locations (5)
Minnesota
- Hennepin Healthcare Research Institute - Minneapolis
- Regents of the University of Minnesota - Advanced Research & Diagnostic - Minneapolis
Georgia
- Foundation for Atlanta Veterans Education and Research, Inc. - Decatur
North Carolina
- Wake Forest University - Winston-Salem
Victoria
- Monash University - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,435 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-08 |
What the registry record for NCT07224139 still lists
NCT07224139 is an observational study that tracks outcomes without assigning an intervention. Its 13,435 participants enrollment target places it among the larger protocols in the corpus, above the 2,707-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (396% higher).
The record links to 3 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07224139 lists 5 locations in 4 states (Minnesota, Georgia, North Carolina).
Frequently Asked Questions
What is clinical trial NCT07224139 about?
NCT07224139 is a clinical study titled "Sex-specific Risk Factors and Trajectories of Blood Biomarkers for Alzheimer's Disease and Related Dementias". Blood-based ADRD biomarkers show tremendous promise as a non-invasive method to predict and diagnose ADRD. We will measure changes in these biomarkers to determine whether their ability to predict ADRD differs by sex or by other characteristics, and develop a sex-specific ADRD risk score for persona...
What is the current status of trial NCT07224139?
This trial is currently active not recruiting. The enrollment target is 13,435 participants. The study started on 2022-07-01. Estimated completion is 2027-08.
What conditions does trial NCT07224139 study?
This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Dysfunction.
Who is sponsoring clinical trial NCT07224139?
This trial is sponsored by Anne Murray, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224139 being conducted?
This trial has 5 study locations across Georgia, Minnesota, North Carolina, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224139's enrollment target sits among peer trials
13,435 8th of 306 higher than 299 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
RECRUITING · Phase 3
-
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
RECRUITING · Phase 4
-
Systemic and Central Inflammation in AD
RECRUITING · Phase 2
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease
RECRUITING · Phase 1
-
Cognitive Neurology Unit Clinical Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT06058767 · 13,764 participants · NA
Preschool Hearing Screening
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI